Form 4: Ideaya Biosciences Director, Scott W. Morrison, Acquires Stock Options

Director Scott W. Morrison acquired stock options in Ideaya Biosciences, Inc. on May 31, 2024.

Summary

• On May 31, 2024, Scott W. Morrison, a director of Ideaya Biosciences, Inc., acquired stock options for 16,200 shares.
• The exercise price of these options is $36.55.
• The options vest on the earlier of the first anniversary of the grant date or immediately prior to the next Annual Meeting, contingent upon continued service on the Board.
• The options expire on May 30, 2034.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing. The acquisition of stock options by a director is generally viewed as a neutral to slightly positive signal, indicating confidence in the company's prospects.

Positives

• The acquisition of stock options by a director signals confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of the options is tied to continued service on the board, suggesting an ongoing commitment.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation in the biotechnology industry.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in biotech companies like Ideaya Biosciences.
• Companies such as Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options as part of their executive compensation plans.
• The vesting schedules and exercise prices are generally aligned with industry norms to incentivize long-term value creation.

Stakeholder Impact

• The acquisition of stock options by a director can be viewed positively by shareholders as it aligns the director's interests with those of the shareholders.

Key Dates